A Phase III, Open Label, Randomized, Multicenter Study Evaluating the Safety and Efficacy of 25 mg and 50 mg Doses of Proellex to Assess Recurrence of Symptoms in the Treatment of Symptomatic Uterine Fibroids

Trial Profile

A Phase III, Open Label, Randomized, Multicenter Study Evaluating the Safety and Efficacy of 25 mg and 50 mg Doses of Proellex to Assess Recurrence of Symptoms in the Treatment of Symptomatic Uterine Fibroids

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Adverse reactions
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 12 Feb 2010 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 03 Aug 2009 Status changed from not yet recruiting to suspended, according to a Repros Therapeutics media release.
    • 01 Jul 2009 Repros has decided to discontinue the use of the higher, 50 mg dose in its ongoing studies in women with chronic symptomatic uterine fibroids, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top